Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2025-02-03 Declaration of Voting R…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is identified by the header 'RNS Number' and contains information mandated by the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1 regarding 'Voting rights and capital'. Specifically, it states the total number of issued shares with voting rights as of a specific date (31 January 2025). This type of mandatory regulatory disclosure concerning the total voting rights denominator is a specific type of regulatory announcement. While it relates to capital structure, it is not a financing activity (CAP) or a share issue (SHA), but rather a periodic regulatory disclosure about voting rights. The closest fit among the provided options for a mandatory, periodic regulatory disclosure that isn't a major financial report (like 10-K or IR) or a specific insider trade (DIRS) is 'Declaration of Voting Results & Voting Rights Announcements' (DVA), as it directly concerns voting rights figures. Given the context of RNS distribution and the nature of the disclosure, DVA is the most precise classification.
2025-02-03 English
IMFINZI RECOMMENDED FOR EU APPROVAL FOR LS-SCLC
Foreign Filer Report
2025-02-03 English
Imfinzi recommended for EU approval for LS-SCLC
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 5232V' and is dated '03 February 2025'. It announces a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding AstraZeneca's drug Imfinzi. The content is a press release detailing clinical trial results and regulatory progress, which is characteristic of a general regulatory announcement disseminated via the RNS system (London Stock Exchange's news service). Since it is a specific announcement of regulatory/clinical news rather than a full financial report (like 10-K or IR) or a general corporate action, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such market news releases not covered by more specific codes like ER or DIV. The document explicitly mentions RNS at the end.
2025-02-03 English
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding percentage for The Capital Group Companies, Inc. in AstraZeneca PLC. Specifically, it shows the number of shares and voting rights before and after a transaction (a 'Sälj' or Sale) on 2025-01-29, resulting in the total holding dropping below the 5% threshold (to 4.9968%). This type of filing, reporting changes in significant share ownership that cross regulatory thresholds, corresponds to a Major Shareholding Notification. The code for this is MRQ.
2025-01-31 Swedish
ENHERTU APPROVED IN US FOR BREAST CANCER POST ET
Foreign Filer Report
2025-01-28 English
Enhertu approved in US for breast cancer post ET
Regulatory Filings Classification · 1% confidence The document is identified by the RNS Number (9331U) and the date stamp (28 January 2025), indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS). The content details a specific regulatory event: the US FDA approval of the drug Enhertu for a new patient population in breast cancer, based on Phase III trial results (DESTINY-Breast06). It also mentions a related milestone payment ($175m) due to Daiichi Sankyo. Since this is a formal announcement of a significant regulatory/commercial event, and not the full annual report (10-K), an earnings release (ER), or a transcript (CT), it fits best under the general 'Regulatory Filings' category (RNS) as it is a broad regulatory news item that doesn't fit the other specific codes like DIV, DIRS, or MANG. Given the document length (over 22k characters) and the detailed nature of the announcement, it is the primary filing itself, not just an announcement of a report (RPA). RNS is the most appropriate general regulatory filing code here.
2025-01-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.